Page 64 - Read Online

Page 10 of 11 Zerehpooshnesfchi et al. Metab Target Organ Damage. 2025;5:15 https://dx.doi.org/10.20517/mtod.2025.04

fatty liver disease nomenclature. Hepatology. 2023;78:1966-86. DOI PubMed PMC
21. Díaz LA, Arab JP, Louvet A, Bataller R, Arrese M. The intersection between alcohol-related liver disease and nonalcoholic fatty liver
disease. Nat Rev Gastroenterol Hepatol. 2023;20:764-83. DOI PubMed
22. Tourkochristou E, Assimakopoulos SF, Thomopoulos K, Marangos M, Triantos C. NAFLD and HBV interplay - related mechanisms
underlying liver disease progression. Front Immunol. 2022;13:965548. DOI PubMed PMC
23. Zheng Q, Zou B, Wu Y, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in
chronic hepatitis B. Aliment Pharmacol Ther. 2021;54:1100-9. DOI PubMed
24. Zhang M, Chen S, Wu X, et al. Persistent steatosis correlates with decreased fibrosis regression during anti-HBV treatment in patients
with chronic HBV infection. J Med Virol. 2023;95:e29156. DOI PubMed
25. Patmore LA, Katwaroe WK, van der Spek D, et al. Association between the presence of metabolic comorbidities and liver-related
events in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2023;21:3089-96.e1. DOI PubMed
26. Lin S, Wang M, Liu Y, et al. Concurrence of HBV infection and non-alcoholic fatty liver disease is associated with higher prevalence
of chronic kidney disease. Clin Res Hepatol Gastroenterol. 2021;45:101483. DOI PubMed
27. Attia D, Abdel Alem S, El-Akel W, et al. Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty
liver disease with hepatitis C virus infection-a population-based study. Aliment Pharmacol Ther. 2022;56:1581-90. DOI PubMed
28. Cheng KL, Wang SW, Cheng YM, Hsieh TH, Wang CC, Kao JH. Prevalence and clinical outcomes in subtypes of metabolic
associated fatty liver disease. J Formos Med Assoc. 2024;123:36-44. DOI PubMed
29. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for
hepatic and extrahepatic disease. Gastroenterology. 2004;126:586-97. DOI PubMed
30. Huang CF, Dai CY, Yeh ML, et al. Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic
hepatitis C virus infection. J Hepatol. 2015;62:512-8. DOI PubMed
31. Younossi ZM, McCullough AJ, Ong JP, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin
Gastroenterol. 2004;38:705-9. DOI PubMed
32. Khattab MA, Eslam M, Mousa YI, et al. Association between metabolic abnormalities and hepatitis C-related hepatocellular
carcinoma. Ann Hepatol. 2012;11:487-94. DOI
33. Eslam M, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Use of HOMA-IR in hepatitis C. J Viral Hepat.
2011;18:675-84. DOI PubMed
34. Lonardo A, Adinolfi LE, Restivo L, et al. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of
a successful pathogen. World J Gastroenterol. 2014;20:7089-103. DOI PubMed PMC
35. Wong RJ, Chou C, Sinha SR, Kamal A, Ahmed A. Ethnic disparities in the association of body mass index with the risk of
hypertension and diabetes. J Community Health. 2014;39:437-45. DOI PubMed
36. Shih CI, Wu KT, Hsieh MH, et al. Severity of fatty liver is highly correlated with the risk of hypertension and diabetes: a cross-
sectional and longitudinal cohort study. Hepatol Int. 2024;18:138-54. DOI PubMed
37. Yu ML, Chuang WL. Path from the discovery to the elimination of hepatitis C virus: honoring the winners of the Nobel prize in
physiology or medicine 2020. Kaohsiung J Med Sci. 2021;37:7-11. DOI PubMed
38. Liu CJ, Seto WK, Yu ML. Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD.
Hepatol Int. 2024;18:897-908. DOI PubMed
39. Carvalho AF, Heilig M, Perez A, Probst C, Rehm J. Alcohol use disorders. Lancet. 2019;394:781-92. DOI PubMed
40. Åberg F, Puukka P, Salomaa V, et al. Combined effects of alcohol and metabolic disorders in patients with chronic liver disease. Clin
Gastroenterol Hepatol. 2020;18:995-7.e2. DOI PubMed
41. Chang Y, Cho YK, Kim Y, et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease:
a cohort study. Hepatology. 2019;69:64-75. DOI PubMed
42. Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat
Genet. 2010;42:21-3. DOI PubMed
43. Petrie E, Gray M, Bril F. Metabolic characteristics of patients with MetALD: caveats of a new definition. Liver Int. 2024;44:2929-38.
DOI PubMed
44. Alboraie M, Butt AS, Piscoya A, et al. Why MASLD lags behind MAFLD: a critical analysis of diagnostic criteria evolution in
metabolic dysfunction-associated liver diseases. Med Sci Monit. 2024;30:e945198. DOI PubMed PMC
45. Holbeck M, DeVries HS, Singal AK. Integrated multidisciplinary management of alcohol-associated liver disease. J Clin Transl
Hepatol. 2023;11:1404-12. DOI PubMed PMC
46. Musto JA, Brown R, Lucey MR. Is there a safe limit for consumption of alcohol? J Hepatol. 2025;82:535-40. DOI PubMed PMC
47. Meijnikman AS, Nieuwdorp M, Schnabl B. Endogenous ethanol production in health and disease. Nat Rev Gastroenterol Hepatol.
2024;21:556-71. DOI PubMed
48. Boniface S, Kneale J, Shelton N. Drinking pattern is more strongly associated with under-reporting of alcohol consumption than socio-
demographic factors: evidence from a mixed-methods study. BMC Public Health. 2014;14:1297. DOI PubMed PMC
49. Joo EJ, Chang Y, Yeom JS, Ryu S. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study.
Hepatology. 2017;65:828-35. DOI PubMed
50. Seto WK. Chronic hepatitis B and metabolic risk factors: a call for rigorous longitudinal studies. World J Gastroenterol. 2019;25:282-
6. DOI PubMed PMC